Continuing Education Activity

Methemoglobinemia is a potentially life-threatening condition characterized by impaired oxygen delivery due to oxidation of hemoglobin iron from the ferrous (Fe2+) to the ferric (Fe3+) state. Ferric hemoglobin is incapable of binding oxygen, resulting in functional anemia and tissue hypoxia. The condition may be congenital or acquired. Congenital forms involve cytochrome b5 reductase deficiency or hemoglobin structural variants. Acquired methemoglobinemia typically arises after exposure to oxidizing agents, including topical anesthetics, nitrates and nitrites, dapsone, and industrial chemicals, such as aniline dyes. Infants, individuals with enzymatic deficiencies, and patients with comorbid oxidative stress face an elevated risk of severe illness.

Clinical manifestations include cyanosis unresponsive to oxygen therapy, headache, fatigue, dyspnea, and, at higher methemoglobin levels, arrhythmias, seizures, or coma. Diagnosis relies on co-oximetry, with pulse oximetry often revealing saturation near 85% despite adequate oxygenation. Treatment focuses on immediate removal of the offending source and prompt administration of methylene blue when symptomatic or significantly elevated levels are present. Alternatives include high-dose ascorbic acid and exchange transfusion in specific populations. Rapid management prevents hypoxic injury, ensuring favorable outcomes.

This activity for healthcare professionals is designed to sharpen learners' skills in evaluating and managing methemoglobinemia. Participants will deepen their understanding of the condition's etiology, risk factors, pathophysiology, clinical presentation, and evidence-based diagnostic and therapeutic recommendations. Greater competence will empower clinicians to collaborate with interprofessional teams providing care for affected individuals.

Objectives:

• Identify clinical and laboratory indicators, considering patient-specific risks, to guide timely treatment in suspected methemoglobinemia cases.
• Apply individualized, evidence-based approaches for managing methemoglobinemia and mitigating its potential complications.
• Improve patient understanding of symptom recognition, trigger avoidance, and treatment adherence to prevent exacerbations and support timely, effective management of methemoglobinemia.
• Collaborate with the interprofessional team to educate, treat, and monitor patients who experience or are at risk for methemoglobinemia to improve overall health outcomes.

Access free multiple choice questions on this topic.

Introduction

Methemoglobinemia is a condition with life-threatening potential in which the oxygen-carrying capacity of circulating hemoglobin is diminished due to the conversion of some or all of the 4 iron species in hemoglobin from the reduced ferrous (Fe2+) or divalent state to the oxidized ferric (Fe3+) or trivalent form. Trivalent iron cannot bind or transport oxygen. This loss of oxygen-carrying capacity produces a functional anemia. Clinical manifestations arise from tissue hypoxia secondary to impaired oxygen delivery.

Etiology

Methemoglobin is present at low levels in the general population and typically does not produce clinical symptoms. Endogenous enzymatic mechanisms reduce methemoglobin iron back to its Fe2+ state. The normal half-life of methemoglobin ranges from 1 to 3 hours, but this interval is prolonged with ongoing oxidative stress.[1][2]

Methemoglobinemia may result from congenital or acquired processes. Congenital forms arise from autosomal recessive defects in cytochrome b5 reductase (CYB5R) or autosomal dominant mutations in globin genes collectively known as hemoglobin M.[3] Multiple hemoglobin M variants have been described, including Boston, Fort Ripley, Hyde Park, Iwate, Kankakee, Osaka, and Saskatoon.[4] Type I congenital methemoglobinemia involves CYB5R defects expressed only in erythrocytes, whereas type II affects all cell types.[5] Hemoglobin M disease encompasses mutations typically located in α or β chains near the heme iron, predisposing the iron to oxidation to the Fe3+ state.[6][7][6]

Acquired methemoglobinemia is significantly more common and results from exposure to substances that oxidize hemoglobin. Oxidation may occur via direct or indirect processes. This exposure produces methemoglobin in quantities that exceed the body’s capacity to reduce the iron within hemoglobin back to the Fe2+ state. Acquired methemoglobinemia may arise from exposure to direct oxidizing agents (eg, benzocaine, prilocaine), indirect oxidants (eg, nitrates), or substances requiring metabolic activation (eg, aniline, dapsone).[8] Classic examples include patient exposure to benzocaine during endoscopy and infant exposure to nitrites in well water. Recreational use of “poppers” has recently emerged as a common source. Xenobiotics associated with methemoglobinemia include, but are not limited to, the following:

• Antimalarial drugs (chloroquine, primaquine) [9]
• Local anesthetics (benzocaine, prilocaine, lidocaine, and bupivacaine) [10][11]
• Dapsone [12][13]
• Nitrites and nitrates[14][15][16]
• Nitroprusside [17]
• Nitric oxide [18]
• Nitroglycerin [19]
• Sulfonamides [20][21]
• Aniline dyes [22][23][24]
• Trinitrotoluene [25]
• Napthalene [26][27][28]

Additional acquired triggers include dietary nitrates, noncolorant industrial chemicals, and environmental toxins. Early recognition of unexplained cyanosis, persistent hypoxia, or sudden-onset symptoms should prompt evaluation for methemoglobinemia.

Epidemiology

Congenital methemoglobinemia due to CYB5R deficiency is very rare, but the actual incidence is unknown. Increased frequency has been reported among Siberian Yakuts, Athabaskans, Eskimos, and Navajo populations.[29] Acquired methemoglobinemia is encountered more frequently than the congenital form, although it remains relatively uncommon. A single-center review of nearly 30,000 transesophageal echocardiograms found an incidence of 0.067%.[30] A systematic review of local anesthetic-related methemoglobinemia cases identified benzocaine as the causative agent in approximately 2/3 of instances.[31] This strong association prompted the U.S. Food and Drug Administration to issue multiple advisories regarding benzocaine-containing oral products.[32]

According to the 2022 Annual Report of the National Poison Data System, exposures to xenobiotics capable of causing methemoglobinemia accounted for less than 0.5% of more than 2 million human exposures reported to poison centers. More common agents included nitrates, nitrites, and local anesthetics.[33] Only a small fraction of these exposures resulted in the development of methemoglobinemia.

Pathophysiology

Hemoglobin is a key protein responsible for oxygen transport in the blood. This molecule is a tetramer consisting of 2 α- and 2 β-chains. Each subunit contains a heme group with an iron moiety responsible for oxygen binding. Methemoglobin forms when the iron in the heme group is oxidized to the Fe3+ state. Any of the 4 iron moieties within a hemoglobin molecule in the Fe3+ form cannot bind oxygen. Trivalent iron induces allosteric changes in hemoglobin, shifting the oxygen-dissociation curve to the left. This shift increases the affinity of Fe2+ iron for oxygen, impairing oxygen release to tissues.[34] The consequence is decreased oxygen delivery, resulting in tissue hypoxia and ischemic injury.

Under normal circumstances, a small fraction of iron oxidizes to the Fe3+ state during routine oxygen transport. Methemoglobin levels are maintained below 1% by the enzyme CYB5R, also known as methemoglobin reductase. CYB5R utilizes reduced nicotinamide adenine dinucleotide (NADH) generated during glycolysis to transform methemoglobin back to functional hemoglobin.[35]

In hemoglobin M disease, a mutation in a gene coding for 1 of several globin proteins replaces histidine with tyrosine.[36] This mutation produces a structural change that predisposes iron to oxidation to the Fe3+ form. Patients with hemoglobin M disease typically have methemoglobin levels between 15% and 30% and generally remain asymptomatic.

An alternate pathway for methemoglobin reduction involves nicotinamide adenine dinucleotide phosphate hydrogen methemoglobin (NADPH-MetHb) reductase. NADPH-MetHb reductase uses NADPH generated by glucose-6-phosphate dehydrogenase (G6PD) in the hexose monophosphate shunt as a source of reducing power. Under normal physiologic conditions, NADPH-MetHb reductase contributes minimally to methemoglobin reversion. During oxidative stress, this alternative pathway may be enhanced by exogenous electron donors such as methylene blue. This connection with G6PD often leads to the misconception that G6PD deficiency itself constitutes a risk factor for methemoglobinemia.

History and Physical

Methemoglobinemia should be considered in patients with dyspnea or cyanosis and hypoxemia refractory to supplemental oxygen, particularly following exposure to a known oxidative agent. Presentation can range from minimally symptomatic to severe. Clinical manifestations occur along a spectrum and include cyanosis, pallor, fatigue, weakness, headache, central nervous system depression, metabolic acidosis, seizures, dysrhythmias, coma, and death. Symptom severity is multifactorial, depending on the percentage of methemoglobin in the circulation, the rate of accumulation, intrinsic clearance capacity, and the patient’s underlying health status. Duration and magnitude of exposure to an oxidizing agent may further influence severity.

Methemoglobin is expressed as a concentration or a percentage, and this measurement is further described in the next section. The percentage of methemoglobin is calculated by dividing the concentration of methemoglobin by the concentration of total hemoglobin, as follows:

% MetHb = [MetHb]/[Total Hb] ×100

*[MetHb] = concentration of methemoglobin; [Total Hb] = total hemoglobin concentration

The percentage of methemoglobin is likely a better indicator of illness severity than overall concentration, as underlying medical conditions influence clinical impact. For example, a methemoglobin concentration of 1.5 g/dL may represent 10% in an otherwise healthy patient with a baseline hemoglobin of 15 g/dL, whereas the same concentration in an anemic patient with a baseline hemoglobin of 8 g/dL represents 18.75%. The former patient retains a functional hemoglobin concentration of 13.5 g/dL and may remain asymptomatic, while the latter patient, with a functional hemoglobin concentration of 6.5 g/dL, may be severely symptomatic despite a methemoglobin percentage below 20%.

This effect may be compounded by decreased oxygen release from functional hemoglobin in the presence of methemoglobin. Any pathology that impairs oxygen delivery, including anemia, congestive heart failure, and chronic obstructive pulmonary disease, can exacerbate the symptoms of methemoglobinemia.

In an otherwise healthy individual, cyanosis may become clinically evident at methemoglobin levels as low as 10%. The classic appearance of “chocolate brown blood” may be present at levels as low as 15%. As the methemoglobin percentage approaches 20%, patients may experience anxiety, light-headedness, and headaches. At levels of 30% to 50%, tachypnea, confusion, and loss of consciousness may occur. Approaching 50%, patients are at risk for seizures, dysrhythmias, metabolic acidosis, coma, and death. Methemoglobin levels above 70% are often fatal (see Image. Methemoglobinemia Symptom Severity by Level).[37]

Evaluation

Methemoglobinemia is a clinical diagnosis based on history and presenting signs, including hypoxemia refractory to supplemental oxygen and the characteristic presence of chocolate-colored blood. Diagnosis is confirmed by arterial or venous blood gas with co-oximetry, which speciates hemoglobin to determine methemoglobin concentration and percentage. Conventional pulse oximeters, which measure peripheral capillary oxygen saturation (SpO2), cannot be used to assess methemoglobinemia severity, as explained below.

Refractory hypoxemia is a significant diagnostic clue. This condition is generally evident on SpO2 measurement based on wavelength detection, but not when calculated from blood gas analysis using the partial pressure of oxygen in the blood (SaO2).

Traditional dual-wavelength pulse oximetry yields inaccurate readings in methemoglobinemia because these devices measure light absorbance at 2 wavelengths—660 and 940 nm. The ratio of absorbance allows differentiation between oxyhemoglobin and deoxyhemoglobin, with the expressed percentage, or SpO2, indicating the measured fraction of hemoglobin that is oxygenated. Methemoglobin absorbs strongly at both wavelengths, producing interference that causes inaccurate SpO2 readings. When methemoglobin levels approach 30% to 35%, the absorbance ratio (A660/A940) reaches 1.0, which corresponds to a SpO2 reading of 85%.[38]

A disproportional, inverse relationship exists between methemoglobin concentration and SpO2. Despite consistently depressed SpO2 readings, values are generally falsely elevated relative to true oxygen saturation and may vary depending on the specific device.

While SpO2 measurements are inaccurate and depressed due to wavelength interference, often reading 75% to 90% even with supplemental oxygen, SaO2 calculations are falsely normal, as these calculations assume that hemoglobin exists only as oxyhemoglobin or deoxyhemoglobin. The difference between the depressed SpO2 measurement and the falsely normal SaO2 calculation is termed the “saturation gap.” This additional diagnostic clue may suggest the presence of a hemoglobinopathy, though this finding is nonspecific and cannot confirm a diagnosis of methemoglobinemia. A saturation gap greater than 5% may be observed in cases with elevated abnormal forms of hemoglobin, such as carboxyhemoglobin, methemoglobin, and sulfhemoglobin.[39]

Treatment / Management

Treatment of methemoglobinemia includes removal of the inciting agent and consideration of antidotal therapy with adjunctive interventions such as methylene blue (tetramethylthionine chloride). High-flow oxygen delivered via a nonrebreather mask increases tissue oxygen delivery and enhances the natural degradation of methemoglobin.

Methylene blue typically acts rapidly and effectively through the secondary pathway of methemoglobin reduction, in which NADPH-MetHb reductase reduces methylene blue to leukomethylene blue using NADPH generated from the G6PD-dependent hexose monophosphate shunt. Leukomethylene blue then serves as an electron donor to reduce methemoglobin to hemoglobin.

Methylene blue treatment is indicated for acquired methemoglobinemia when levels exceed 20% to 30% or the patient is symptomatic, even at lower levels. In cases of suspected severe methemoglobinemia, treatment should not be delayed pending confirmatory laboratory values. The recommended dose is 1 to 2 mg/kg (0.1 to 0.2 mL/kg of 1% solution) administered intravenously over 5 minutes. The dose may be repeated after 30 to 60 minutes if symptoms persist or methemoglobin levels remain above the treatment threshold.

Practitioners should be aware of the side-effect profile of methylene blue. Benign effects include green or blue discoloration of urine, for which patients should be forewarned. Significant adverse effects arise from methylene blue functioning as both an oxidizing agent and an inhibitor of monoamine oxidase A. As an oxidizing agent, methylene blue can precipitate methemoglobinemia or hemolysis when doses are high or reduction is inadequate. Meanwhile, concurrent administration with serotonergic agents may predispose patients to serotonin syndrome.[40]

Caution is warranted in neonates, who are highly sensitive to oxidizing agents. Methylene blue is classified as pregnancy category X by the U.S. Food and Drug Administration, indicating confirmed fetal abnormalities from in utero exposure. Risk-benefit evaluation is recommended when treating pregnant patients.[41][42]

Although methylene blue use in G6PD deficiency is controversial due to reduced NADPH levels, it is not contraindicated and should be administered cautiously. Many G6PD-deficient patients retain sufficient enzymatic activity to generate an adequate response, and thus, treatment should not be withheld. Hemolysis in individuals with G6PD deficiency has been observed at doses exceeding 5 mg/kg, more than twice the recommended dose.[43]

If methylene blue administration is ineffective after a 2nd dose, underlying conditions—such as, but not limited to, G6PD deficiency and NADPH-MetHb reductase deficiency—should be considered as potential causes of treatment refractoriness. Methemoglobinemia alone is not an indication to screen for these disorders.

Additional options when methylene blue is ineffective or contraindicated include ascorbic acid, exchange transfusion, and hyperbaric oxygen therapy (HBOT).[44] High-dose ascorbic acid (vitamin C), up to 10 g intravenously per dose, may be considered for treatment. However, this intervention is generally ineffective and is not standard of care. High-dose administration increases urinary oxalate excretion and may predispose patients with renal insufficiency to renal failure due to hyperoxaluria.[45]

Exchange transfusion treats methemoglobinemia by replacing the patient’s blood with donor blood free of methemoglobin. Case reports describe successful outcomes when methylene blue was ineffective or unavailable.[46][47] HBOT increases dissolved oxygen in the bloodstream, providing additional time for endogenous mechanisms to reduce methemoglobin.

Differential Diagnosis

Cyanosis may result from a variety of conditions that cause acute or chronic hypoxia. The differential diagnosis includes pulmonary, cardiac, hematologic, and toxicologic causes, such as the following

• Exacerbation of asthma or chronic obstructive pulmonary disease
• Opioid overdose
• Acute pulmonary edema
• Aggravation of congestive heart failure
• Cyanotic congenital heart disease
• Peripheral cyanosis
• Polycythemia
• Sulfhemoglobinemia

Bluish skin discoloration is a nonspecific finding that may result from a variety of conditions, including the following:

• Acrodermatitis enteropathica
• Amiodarone-induced skin pigmentation
• Argyria
• Skin contact with blue dye

Differentiating between the potential causes of cyanosis and bluish skin discoloration involves integrating clinical history, physical examination, and relevant laboratory or imaging studies. This approach ensures timely recognition of critical conditions while avoiding unnecessary or inappropriate interventions.

Prognosis

Most patients with mild methemoglobinemia do not require treatment beyond discontinuation of the offending agent. Patients exhibiting signs of end-organ damage, such as cardiac ischemia, altered mental status, significant laboratory abnormalities, or persistent symptoms, may require treatment with methylene blue. Symptomatic patients, particularly those receiving methylene blue, should be considered for hospital admission.

Consultations

All cases of methemoglobinemia should be managed in consultation with a medical toxicologist. Coordination with such a specialist helps tailor management strategies to patient-specific risks and comorbidities.

Pearls and Other Issues

Key considerations in the management of methemoglobinemia include the following:

• Diagnosis of methemoglobinemia should be suspected based on clinical presentation and confirmed with blood gas co-oximetry.
• Diagnostic clues include refractory hypoxemia (oxygen saturation remaining in the 80% range despite supplementation), a saturation gap, and chocolate-colored blood.
• Methylene blue is a monoamine oxidase inhibitor and may precipitate serotonin toxicity when administered to patients taking other serotonergic agents.
• Methylene blue should be administered cautiously and judiciously in infants and patients with G6PD deficiency, though it is not absolutely contraindicated.
• Alternative treatment modalities include exchange transfusion and HBOT.

Patient education should focus on minimizing exposure to substances that increase methemoglobin and identifying early warning signs. Prompt medical attention is essential if symptoms develop, and treatment options should be discussed to ensure safe and effective care.

Enhancing Healthcare Team Outcomes

Methemoglobinemia is a potentially life-threatening condition that can arise from congenital, acquired, or mixed etiologies. Early recognition is critical to prevent ischemic complications associated with severe disease. The interprofessional team—including emergency physicians, hospitalists, nurses, pharmacists, and advanced practitioners—must collaborate to diagnose, monitor, and treat affected patients. Cases secondary to xenobiotic exposure should be managed in consultation with a medical toxicologist or poison control center. Escalation to intensive care may be required when prolonged monitoring or treatment is necessary or significant adverse outcomes arise from elevated methemoglobin.

Healthcare providers should be familiar with xenobiotics associated with methemoglobinemia, whether administered for therapy or ingested in overdose, especially when prescribing these agents. All providers share responsibility for patient education regarding potential side effects, recognition of early signs and symptoms, and guidance on when to seek emergency care.

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Umbreit J. Methemoglobin--it's not just blue: a concise review. Am J Hematol. 2007 Feb;82(2):134-44. [PubMed: 16986127]

2.

Thom CS, Dickson CF, Gell DA, Weiss MJ. Hemoglobin variants: biochemical properties and clinical correlates. Cold Spring Harb Perspect Med. 2013 Mar 01;3(3):a011858. [PMC free article: PMC3579210] [PubMed: 23388674]

3.

Curry S. Methemoglobinemia. Ann Emerg Med. 1982 Apr;11(4):214-21. [PubMed: 7073040]

4.

Haymond S, Cariappa R, Eby CS, Scott MG. Laboratory assessment of oxygenation in methemoglobinemia. Clin Chem. 2005 Feb;51(2):434-44. [PubMed: 15514101]

5.

Kedar PS, Gupta V, Warang P, Chiddarwar A, Madkaikar M. Novel mutation (R192C) in CYB5R3 gene causing NADH-cytochrome b5 reductase deficiency in eight Indian patients associated with autosomal recessive congenital methemoglobinemia type-I. Hematology. 2018 Sep;23(8):567-573. [PubMed: 29482478]

6.

Percy MJ, Lappin TR. Recessive congenital methaemoglobinaemia: cytochrome b(5) reductase deficiency. Br J Haematol. 2008 May;141(3):298-308. [PubMed: 18318771]

7.

Spears F, Banerjee A. Hemoglobin M variant and congenital methemoglobinemia: methylene blue will not be effective in the presence of hemoglobin M. Can J Anaesth. 2008 Jun;55(6):391-2. [PubMed: 18566207]

8.

Bradberry SM. Occupational methaemoglobinaemia. Mechanisms of production, features, diagnosis and management including the use of methylene blue. Toxicol Rev. 2003;22(1):13-27. [PubMed: 14579544]

9.

Rizvi I, Zaman S, Zaidi N, Asif MS, Abdali N. Acute life-threatening methaemoglobinaemia following ingestion of chloroquine. BMJ Case Rep. 2012 Mar 20;2012 [PMC free article: PMC3316854] [PubMed: 22605715]

10.

Williams RT, Fischer BG. Benzocaine-Induced Methemoglobinemia After Nasogastric Tube Insertion. JAMA Intern Med. 2025 Apr 01;185(4):457-458. [PubMed: 39960724]

11.

Rangatchew F, Schoelzer L, Drzewiecki KT, Holmgaard R. EMLA cream in burns: A systematic review of safety, analgesic efficacy, and effects on burn pathophysiology. J Plast Reconstr Aesthet Surg. 2024 Aug;95:386-401. [PubMed: 39018678]

12.

Veasey JV, Souza BCM, Valinoto GCJ. Dapsone-induced methemoglobinemia in a child with leprosy. An Bras Dermatol. 2025 Mar-Apr;100(2):391-394. [PMC free article: PMC11963016] [PubMed: 39794213]

13.

Belzer A, Krasowski MD. Causes of acquired methemoglobinemia - A retrospective study at a large academic hospital. Toxicol Rep. 2024 Jun;12:331-337. [PMC free article: PMC10965427] [PubMed: 38544956]

14.

Aijaz A, Bhat A, Chisti H, Jeevaraj VS, Hamid M. When Pleasure Painted the Blood Blue: A Case of Popper-Induced Methemoglobinemia. Cureus. 2025 Aug;17(8):e89694. [PMC free article: PMC12416778] [PubMed: 40926924]

15.

Alkhateeb W, Luthra G, Almatroud L, Saleh A, Landa E. From Poppers to Peril: Recreational Nitrite-Induced Methemoglobinemia. Cureus. 2024 Aug;16(8):e67435. [PMC free article: PMC11415308] [PubMed: 39310584]

16.

Idries IY, Khristoforov V, Duddala S, Duong YV, Zaman M. Out of the Blue: Methemoglobinemia Associated With the Use of Amyl Nitrite in Rush Poppers for Erectile Stimulation. Cureus. 2023 Jun;15(6):e41201. [PMC free article: PMC10387288] [PubMed: 37525797]

17.

Jacka MJ, Kruger M, Glick N. Methemoglobinemia after transesophageal echocardiography: a life-threatening complication. J Clin Anesth. 2006 Feb;18(1):52-4. [PubMed: 16517334]

18.

Bühl T, Cenci S, Gianni S, Fakhr BS, Valsecchi C, Yu B, Bittner EA, Berra L. Predictors of methemoglobin formation in high-dose inhaled nitric oxide therapy: A retrospective cohort study. Nitric Oxide. 2026 Feb;160:35-43. [PubMed: 41274489]

19.

Imani F, Behseresht A, Pourfakhr P, Shariat Moharari R, Etezadi F, Khajavi M. Prevalence of Abnormal Methemoglobinemia and Its Determinants in Patients Receiving Nitroglycerin During Anesthesia. Anesth Pain Med. 2019 Jun;9(3):e85852. [PMC free article: PMC6712357] [PubMed: 31497516]

20.

Cannon RD, Wagner M, Jacoby JL. Troponin leak associated with drug-induced methemoglobinemia. Am J Emerg Med. 2014 Oct;32(10):1295.e3-4. [PubMed: 24686024]

21.

Kawasumi H, Tanaka E, Hoshi D, Kawaguchi Y, Yamanaka H. Methemoglobinemia induced by trimethoprim-sulfamethoxazole in a patient with systemic lupus erythematosus. Intern Med. 2013;52(15):1741-3. [PubMed: 23903510]

22.

Lee CH, Kim SH, Kwon DH, Jang KH, Chung YH, Moon JD. Two cases of methemoglobinemia induced by the exposure to nitrobenzene and aniline. Ann Occup Environ Med. 2013 Nov 01;25(1):31. [PMC free article: PMC3916109] [PubMed: 24475977]

23.

Gupta N, Dhagia S, Kelaiya A, Sama R, Padhy K. Exchange transfusion as a therapeutic modality for aniline dye-induced methaemoglobinaemia. Natl Med J India. 2024 Jul-Aug;37(4):195-199. [PubMed: 39448536]

24.

Lečbychová K, Káňová M, Dzurňáková P, Blahutová Š, Romanová T, Buršík D. Aniline-induced refractory methemoglobinemia in polytrauma: successful management with erythrocytapheresis. Int J Emerg Med. 2025 Nov 06;18(1):232. [PMC free article: PMC12590686] [PubMed: 41199176]

25.

Kim D, Lee Y, Jeong SY, Lee H. Acute methemoglobinemia after a blast injury: a case report. J Trauma Inj. 2022 Aug;35(Suppl 1):S15-S17. [PMC free article: PMC11309156] [PubMed: 39381164]

26.

Orhan Ö, Talay MN. Methemoglobinemia and acute ıntravascular hemolysis after naphthalene poisoning in a pediatric patient. Arch Argent Pediatr. 2024 Apr 01;122(2):e202310095. [PubMed: 37801672]

27.

Thangatorai R. Naphthalene-Induced Acute Oxidative Hemolysis With Methemoglobinemia in Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency. Cureus. 2022 Mar;14(3):e23496. [PMC free article: PMC9035485] [PubMed: 35494903]

28.

Anand V, Venkatesan DK, T P, Naseem M, Rathia SK. Methemoglobinemia Secondary to a Traditional Healing Practice Using Mothballs: A Need of Pediatric Vigilance. Cureus. 2023 Jun;15(6):e41192. [PMC free article: PMC10387263] [PubMed: 37525810]

29.

Burtseva TE, Ammosova TN, Protopopova NN, Yakovleva SY, Slobodchikova MP. Enzymopenic Congenital Methemoglobinemia in Children of the Republic of Sakha (Yakutia). J Pediatr Hematol Oncol. 2017 Jan;39(1):42-45. [PubMed: 27879543]

30.

Kane GC, Hoehn SM, Behrenbeck TR, Mulvagh SL. Benzocaine-induced methemoglobinemia based on the Mayo Clinic experience from 28 478 transesophageal echocardiograms: incidence, outcomes, and predisposing factors. Arch Intern Med. 2007 Oct 08;167(18):1977-82. [PubMed: 17923598]

31.

Guay J. Methemoglobinemia related to local anesthetics: a summary of 242 episodes. Anesth Analg. 2009 Mar;108(3):837-45. [PubMed: 19224791]

32.

Nappe TM, Pacelli AM, Katz K. An Atypical Case of Methemoglobinemia due to Self-Administered Benzocaine. Case Rep Emerg Med. 2015;2015:670979. [PMC free article: PMC4383305] [PubMed: 25874137]

33.

Gummin DD, Mowry JB, Beuhler MC, Spyker DA, Rivers LJ, Feldman R, Brown K, Pham NPT, Bronstein AC, DesLauriers C. 2022 Annual Report of the National Poison Data System^® (NPDS) from America's Poison Centers^®: 40th Annual Report. Clin Toxicol (Phila). 2023 Oct;61(10):717-939. [PubMed: 38084513]

34.

Wright RO, Lewander WJ, Woolf AD. Methemoglobinemia: etiology, pharmacology, and clinical management. Ann Emerg Med. 1999 Nov;34(5):646-56. [PubMed: 10533013]

35.

Skold A, Cosco DL, Klein R. Methemoglobinemia: pathogenesis, diagnosis, and management. South Med J. 2011 Nov;104(11):757-61. [PubMed: 22024786]

36.

Nagatomo S, Shoji M, Terada T, Nakatani K, Shigeta Y, Hirota S, Yanagisawa S, Kubo M, Kitagawa T, Nagai M, Ohki M, Park SY, Shibayama N. Heme-bound tyrosine vibrations in hemoglobin M: Resonance Raman, crystallography, and DFT calculation. Biophys J. 2022 Jul 19;121(14):2767-2780. [PMC free article: PMC9382339] [PubMed: 35689380]

37.

Wilkerson RG. Getting the blues at a rock concert: a case of severe methaemoglobinaemia. Emerg Med Australas. 2010 Oct;22(5):466-9. [PubMed: 21040486]

38.

Chan ED, Chan MM, Chan MM. Pulse oximetry: understanding its basic principles facilitates appreciation of its limitations. Respir Med. 2013 Jun;107(6):789-99. [PubMed: 23490227]

39.

Akhtar J, Johnston BD, Krenzelok EP. Mind the gap. J Emerg Med. 2007 Aug;33(2):131-2. [PubMed: 17692762]

40.

Ramsay RR, Dunford C, Gillman PK. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol. 2007 Nov;152(6):946-51. [PMC free article: PMC2078225] [PubMed: 17721552]

41.

Grauman Neander N, Loner CA, Rotoli JM. The Acute Treatment of Methemoglobinemia in Pregnancy. J Emerg Med. 2018 May;54(5):685-689. [PubMed: 29627348]

42.

Wallace B, Doran N, Vincent C. Management of isopropyl nitrate-induced methaemoglobinaemia in pregnancy. BMJ Case Rep. 2024 Jul 24;17(7) [PubMed: 39053919]

43.

KELLERMEYER RW, TARLOV AR, BREWER GJ, CARSON PE, ALVING AS. Hemolytic effect of therapeutic drugs. Clinical considerations of the primaquine-type hemolysis. JAMA. 1962 May 05;180:388-94. [PubMed: 14454972]

44.

Cho Y, Park SW, Han SK, Kim HB, Yeom SR. A Case of Methemoglobinemia Successfully Treated with Hyperbaric Oxygenation Monotherapy. J Emerg Med. 2017 Nov;53(5):685-687. [PubMed: 28838565]

45.

Lee KW, Park SY. High-dose vitamin C as treatment of methemoglobinemia. Am J Emerg Med. 2014 Aug;32(8):936. [PubMed: 24972962]

46.

Silwal P, Sah SK, Adhikari R, Maharjan S, Vaidya N, Basnet S, Bhatt A. Nitrobenzene induced methemoglobinemia treated with manual exchange transfusion in a resource-limited setting: a case report. Ann Med Surg (Lond). 2025 Apr;87(4):2449-2452. [PMC free article: PMC11981287] [PubMed: 40212171]

47.

Goyal R, Bora R, Jain A, Bohra GK. When methylene blue fails: a case of methemoglobinemia induced by azoxystrobin and propiconazole managed by exchange transfusion. Int J Emerg Med. 2025 Nov 03;18(1):227. [PMC free article: PMC12581553] [PubMed: 41184768]

Disclosure: Richard Chen declares no relevant financial relationships with ineligible companies.

Disclosure: Thomas Nappe declares no relevant financial relationships with ineligible companies.